Two closely related env antigens from the same patient elicited different spectra of neutralizing antibodies against heterologous HIV-1 isolates

Journal of Virology

Volumn 85, Issue 10, 2011, Pages 4927-4936

  Vaine, Michael ^a   Duenas Decamp, Maria ^a   Peters, Paul ^a   Liu, Qin ^a   Arthos, James ^b   Wang, Shixia ^a   Clapham, Paul ^a   Lu, Shan ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B33 GLYCOPROTEIN GP 120; CD4 ANTIGEN; GLYCOPROTEIN GP 120; LN40 GLYCOPROTEIN GP 120; NEUTRALIZING ANTIBODY; RECOMBINANT GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA IMMUNIZATION; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; RABBIT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; BRAIN; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; LYMPH NODES; RABBITS; VIRAL TROPISM;

HUMAN IMMUNODEFICIENCY VIRUS 1; ORYCTOLAGUS CUNICULUS;

EID: 79955381435     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00081-11     Document Type: Article

References (35)

1. Amanna, I. J., N. E. Carlson, and M. K. Slifka. 2007. Duration of humoral immunity to common viral and vaccine antigens. N. Engl. J. Med. 357:1903-1915.
2. Binley, J. M., et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82:11651-11668.
3. Burton, D. R., and R. A. Weiss. 2010. A boost for HIV vaccine design. Science 329:770-773.
4. Crooks, E. T., et al. 2007. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology 366:245-262.
5. Derby, N. R., et al. 2006. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterolo-gous HIV-1 infection. J. Virol. 80:8745-8762.
6. Duenas-Decamp, M. J., and P. R. Clapham. 2010. HIV-1 gp120 determinants proximal to the CD4 binding site shift protective glycans that are targeted by monoclonal antibody 2G12. J. Virol. 84:9608-9612.
7. Duenas-Decamp, M. J., P. Peters, D. Burton, and P. R. Clapham. 2008. Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop. J. Virol. 82:5807-5814.
8. Duenas-Decamp, M. J., P. J. Peters, D. Burton, and P. R. Clapham. 2009. Determinants flanking the CD4 binding loop modulate macrophage tropism of human immunodeficiency virus type 1 R5 envelopes. J. Virol. 83:2575-2583.
9. Dunfee, R. L., et al. 2006. The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc. Natl. Acad. Sci. U. S. A. 103:15160-15165.
10. Flynn, N. M., et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654- 665.
11. Gilbert, P. B., et al. 2005. Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J. Infect. Dis. 191:666-677.
12. Johnston, M. I., and A. S. Fauci. 2008. An HIV vaccine: challenges and prospects. N. Engl. J. Med. 359:888-890.
13. Kwong, P. D., et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
14. Li, M., et al. 2005. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79:10108-10125.
15. Li, Y., et al. 2008. Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82:638-651.
16. Li, Y., et al. 2007. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13:1032-1034.
17. Lu, S., J. M. Grimes Serrano, and S. Wang. 2010. Polyvalent HIV vaccines. Current HIV Res. 8:622-629.
18. Montefiori, D. C. 2004. Evaluating neutralizing antibodies against HIV, SIV and SHIV in luciferase reporter gene assays, p. 1-15. In J. E. Coligan, A. M. Kruisbeek, D. H. Margullies, E. M. Shevach, and W. Strober (ed.), Current protocols in immunology, vol. 12. John Wiley, Hoboken, NJ.
19. Peters, P. J., et al. 2004. Biological analysis of human immunodeficiency virus type 1 R5 envelopes amplified from brain and lymph node tissues of AIDS patients with neuropathology reveals two distinct tropism phenotypes and identifies envelopes in the brain that confer an enhanced tropism and fusigenicity for macrophages. J. Virol. 78:6915-6926.
20. Peters, P. J., et al. 2008. Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors. Retrovirology 5:5.
21. Peters, P. J., et al. 2006. Non-macrophage-tropic human immunodeficiency virus type 1 R5 envelopes predominate in blood, lymph nodes, and semen: implications for transmission and pathogenesis. J. Virol. 80:6324-6332.
22. Pitisuttithum, P., et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661- 1671.
23. Rerks-Ngarm, S., et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
24. Scheid, J. F., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
25. Stamatatos, L., L. Morris, D. R. Burton, and J. R. Mascola. 2009. Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? Nat. Med. 15:866-870.
26. Vaine, M., et al. 2008. Improved induction of antibodies against key neutralizing epitopes by HIV-1 gp120 DNA prime-protein boost vaccination compared to gp120 protein only vaccination. J. Virol. 82:7369-7378.
27. Vaine, M., S. Wang, A. Hackett, J. Arthos, and S. Lu. 2010. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity. Vaccine 28:2999-3007.
28. Vaine, M., et al. 2010. Profiles of human serum antibody responses elicited by three leading HIV vaccines focusing on the induction of Env-specific antibodies. PLoS One 5:e13916. doi:10.1371/journal.pone.0013916.
29. Walker, B. D., and D. R. Burton. 2008. Toward an AIDS vaccine. Science 320:760-764.
30. Wang, S., et al. 2005. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J. Virol. 79:7933-7937.
31. Reference deleted.
32. Wang, S., et al. 2008. Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 26:1098-1110.
33. Wang, S., et al. 2006. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 350:34-47.
34. Wu, X., et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
35. Zhang, P. F., et al. 2007. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc. Natl. Acad. Sci. U. S. A. 104:10193-10198.